Publications by authors named "Charles J Ryan"

100Publications

Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.

Clin Genitourin Cancer 2020 Aug 29. Epub 2020 Aug 29.

Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.08.008DOI Listing
August 2020

Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in , and on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer.

Am J Clin Exp Urol 2020 15;8(4):106-115. Epub 2020 Aug 15.

Division of Hematology, Oncology & Transplantation, Department of Medicine, University of Minnesota Minneapolis, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486539PMC
August 2020

Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.

Urol Oncol 2020 Oct 8;38(10):793.e1-793.e11. Epub 2020 Aug 8.

Department of Medicine, Division of Hematology/Oncology and Transplantation, University of Minnesota, Minneapolis, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.07.012DOI Listing
October 2020

Androgen hazards with COVID-19.

Endocr Relat Cancer 2020 04 24;27(6):E1-E3. Epub 2020 Apr 24.

Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-20-0133DOI Listing
April 2020

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Eur Urol 2020 04 27;77(4):508-547. Epub 2020 Jan 27.

University of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.01.012DOI Listing
April 2020

Diet and lifestyle considerations for patients with prostate cancer.

Urol Oncol 2020 03 18;38(3):105-117. Epub 2019 Jul 18.

Department of Urology, University of California San Francisco, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.06.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293879PMC
March 2020

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.

Eur Urol Oncol 2018 05 15;1(1):78-82. Epub 2018 May 15.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.03.010DOI Listing
May 2018

Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:309-320. Epub 2019 May 17.

1 Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_239041DOI Listing
January 2019

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Prostate Cancer Prostatic Dis 2020 03 3;23(1):66-73. Epub 2019 May 3.

Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0152-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825875PMC
March 2020

Hard Problems Need "Soft" Science: Integrating Quality of Life into Treatment Decision Making.

Eur Urol 2019 06 12;75(6):948-949. Epub 2019 Jan 12.

Department of Medicine and Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838193000
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2019.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659108PMC
June 2019

Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.

Cancer 2019 02 16;125(3):453-462. Epub 2018 Nov 16.

Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31826
Publisher Site
http://dx.doi.org/10.1002/cncr.31826DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340740PMC
February 2019

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

Clin Genitourin Cancer 2019 Feb 24;17(1):e92-e96. Epub 2018 Sep 24.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.013DOI Listing
February 2019

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Am Soc Clin Oncol Educ Book 2018 May;38:363-371

From the Division of Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; Division of Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, University of California-San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_200967
Publisher Site
http://dx.doi.org/10.1200/EDBK_200967DOI Listing
May 2018

Genetic Variation in the Androgen Receptor and Measures of Plasma Testosterone Levels Suggest Androgen Dysfunction in Alzheimer's Disease.

Front Neurosci 2018 7;12:529. Epub 2018 Aug 7.

Department of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fnins.2018.00529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090298PMC
August 2018

BRCAness and prostate cancer: diagnostic and therapeutic considerations.

Prostate Cancer Prostatic Dis 2018 11 21;21(4):488-498. Epub 2018 Aug 21.

Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0069-2DOI Listing
November 2018

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Cell 2018 07 19;174(3):758-769.e9. Epub 2018 Jul 19.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, USA; Division of Hematology and Oncology, Department of Medicine, UCSF, San Francisco, CA, USA; Department of Radiation Oncology, UCSF, San Francisco, CA, USA; Department of Urology, UCSF, San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2018.06.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425931PMC
July 2018

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

J Clin Oncol 2018 08 9;36(24):2492-2503. Epub 2018 Jul 9.

Rahul Aggarwal, Li Zhang, Felix Y. Feng, Paul Lloyd, Jack Youngren, Adam Foye, Denise Playdle, Charles J. Ryan, and Eric J. Small, University of California San Francisco, San Francisco; Alana S. Weinstein, Verena Friedl, Can Zhang, Christopher K. Wong, Vlado Uzunangelov, Artem Sokolov, Yulia Newton, and Joshua M. Stuart, University of California Santa Cruz, Santa Cruz; Owen N. Witte and Matthew Rettig, University of California Los Angeles, Los Angeles; Christopher P. Evans and Primo Lara, University of California Davis, Davis, CA; Jiaoti Huang, Duke University, Durham, NC; Joshi J. Alumkal, George V. Thomas, and Tomasz M. Beer, Oregon Health Sciences University, Portland, OR; Martin Gleave and Kim N. Chi, University of British Columbia, Vancouver, British Columbia, Canada; Lawrence True, University of Washington, Seattle, WA; Himisha Beltran and Mark A. Rubin, Weill Cornell Medicine, New York, NY; and Francesca Demichelis, University of Trento, Trento, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6880DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366813PMC
August 2018

Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways.

Ann Transl Med 2018 May;6(9):161

Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.05.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985268PMC
May 2018

At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials.

Oncologist 2018 10 26;23(10):1242-1249. Epub 2018 Apr 26.

Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0628DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263122PMC
October 2018

Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.

Clin Genitourin Cancer 2018 06 27;16(3):184-190.e2. Epub 2017 Dec 27.

Division of Hematology/Oncology, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.12.004DOI Listing
June 2018

A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer.

JCO Clin Cancer Inform 2017 11;1:1-15

Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874023PMC
November 2017

Treatment strategies in low-volume metastatic castration-resistant prostate cancer.

Curr Opin Urol 2017 Nov;27(6):596-603

aDivision of Hematology/Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California bDepartment of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000436DOI Listing
November 2017

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Ther Adv Med Oncol 2017 May 22;9(5):319-333. Epub 2017 Mar 22.

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017698644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424866PMC
May 2017

Impact of Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.

J Nucl Med 2017 12 18;58(12):1956-1961. Epub 2017 May 18.

UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.117.192
Publisher Site
http://dx.doi.org/10.2967/jnumed.117.192476DOI Listing
December 2017

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.

Oncologist 2017 05 17;22(5):503-e43. Epub 2017 Mar 17.

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423513PMC
May 2017

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Clin Cancer Res 2017 Jul 17;23(14):3544-3551. Epub 2017 Feb 17.

Sidney Kimmel Center for Prostate and Urologic Cancers, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543693PMC
July 2017

68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

J Nucl Med 2017 Jan 22;58(1):81-84. Epub 2016 Sep 22.

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.116.181800DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209643PMC
January 2017

Utility of novel androgen receptor therapies in the real world: A nuanced approach.

Urol Oncol 2016 08 21;34(8):340-7. Epub 2016 Jul 21.

Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.05.002DOI Listing
August 2016

DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.

Oncologist 2016 08 17;21(8):940-5. Epub 2016 Jun 17.

Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978560PMC
August 2016

Targeting the Androgen Receptor: Remaining questions and future directions.

Authors:
Charles J Ryan

Urol Oncol 2016 08 3;34(8):339. Epub 2016 Jun 3.

Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.05.001DOI Listing
August 2016

Approaches to minimize castration in the treatment of advanced prostate cancer.

Urol Oncol 2016 08 2;34(8):368-74. Epub 2016 Mar 2.

Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.02.001DOI Listing
August 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies.

J Comp Eff Res 2016 Jan 21;5(1):5-7. Epub 2015 Dec 21.

Genitourinary Medical Oncology Program, Division of Hematology & Oncology, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer.15.61DOI Listing
January 2016

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach.

J Natl Compr Canc Netw 2015 Jun;13(6):811-22

From Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts; Division of Medical Oncology, Moffitt Cancer Center, Tampa, Florida; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Division of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Division of Oncology, Stanford University Medical Center, Palo Alto, California; Division of Hematology/Oncology, The University of California, San Francisco, California; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0094DOI Listing
June 2015

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.

Cancer Immunol Res 2015 Sep 12;3(9):1008-16. Epub 2015 May 12.

Division of Hematology/Oncology, University of California, San Francisco, California. UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561203PMC
September 2015

Somatostatin imaging of neuroendocrine-differentiated prostate cancer.

Clin Nucl Med 2015 Jun;40(6):540-1

From the *Department of Radiology and Biomedical Imaging, †Division of Hematology/Oncology, Department of Medicine, Departments of ‡Pathology, §Urology, and ∥Radiation Oncology, University of California San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000000776DOI Listing
June 2015

Kidney cancer, version 3.2015.

J Natl Compr Canc Netw 2015 Feb;13(2):151-9

From Memorial Sloan Kettering Cancer Center; The University of Texas MD Anderson Cancer Center; Huntsman Cancer Institute at the University of Utah; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; City of Hope Comprehensive Cancer Center; Roswell Park Cancer Institute;University of Washington/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0022DOI Listing
February 2015

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

J Clin Oncol 2015 Apr 26;33(12):1356-63. Epub 2015 Jan 26.

Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.3875DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881370PMC
April 2015

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

J Clin Oncol 2015 Mar 20;33(7):786-809. Epub 2015 Jan 20.

Gregory Masters, Helen F. Graham Cancer Center, Newark, DE; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Howard H. Bailey, University of Wisconsin Hospital and Clinics, Madison, WI; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Harold Burstein and Lisa R. Diller, Dana-Farber Cancer Institute; Don S. Dizon, Massachusetts General Hospital, Boston, MA; Howard A. Fine, New York University Langone Medical Center; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Gregory P. Kalemkerian, University of Michigan Health System; Sandra L. Wong, University of Michigan, Ann Arbor, MI; Mark Moasser, University of California San Francisco School of Medicine; Charles J. Ryan and Alan P. Venook, University of California San Francisco, San Francisco; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Michael N. Neuss, Vanderbilt-Ingram Cancer Center, Nashville, TN; Olatoyosi Odenike, University of Chicago; and Jyoti D. Patel, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/01/16/JCO.2014.59
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.59.9746
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.9746DOI Listing
March 2015

Hair, hormones, and high-risk prostate cancer.

J Clin Oncol 2015 Feb 29;33(5):386-7. Epub 2014 Dec 29.

University of California, San Francisco, San Francisco, CA

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/12/29/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.5588
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.5588DOI Listing
February 2015

Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies.

Cancer 2015 Feb 18;121(3):361-71. Epub 2014 Sep 18.

Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28929DOI Listing
February 2015

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Oncologist 2014 Oct 17;19(10):1012-8. Epub 2014 Sep 17.

Department of Medicine, Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA; Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA; Educational Concepts Group, LLC, Atlanta, Georgia, USA; Tulane Cancer Center, Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200991PMC
October 2014

Friend or foe: the bifunctional role of steroid hormones in prostate cancer.

Oncology (Williston Park) 2014 May;28(5):408, 410

View Article

Download full-text PDF

Source
May 2014

Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

Clin Genitourin Cancer 2014 Oct 28;12(5):e167-72. Epub 2014 Mar 28.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.03.010DOI Listing
October 2014

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

J Clin Oncol 2014 Apr 3;32(11):1143-50. Epub 2014 Mar 3.

Matthew R. Smith and Philip Saylor, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben Sanford, Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC; Charles J. Ryan and Eric J. Small, University of California at San Francisco, San Francisco, CA; Walter Stadler, University of Chicago; Nirmala Bhoopalam, Loyola University of Chicago, Chicago, IL; Arif Hussain, University of Maryland, Baltimore, MD; Nicholas Vogelzang, Nevada Cancer Research Foundation CCOP, Las Vegas, NV; Ralph J. Hauke, University of Nebraska, Omaha, NE; J. Paul Monk, Ohio State University, Columbus, OH; W. Kevin Kelly, Thomas Jefferson University, Philadelphia, PA; Michael Morris, Memorial Sloan-Kettering Cancer Center, New York, NY; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.6500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970172PMC
April 2014

Kidney cancer, version 2.2014.

J Natl Compr Canc Netw 2014 Feb;12(2):175-82

From 1Memorial Sloan-Kettering Cancer Center; 2The University of Texas MD Anderson Cancer Center; 3Huntsman Cancer Institute at the University of Utah; 4Dana-Farber/Brigham and Women's Cancer Center; 5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 6University of Alabama at Birmingham Comprehensive Cancer Center; 7Vanderbilt-Ingram Cancer Center; 8UC San Diego Moores Cancer Center; 9Moffitt Cancer Center; 10Stanford Cancer Institute; 11The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 12Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 13University of Colorado Cancer Center; 14City of Hope Comprehensive Cancer Center; 15Roswell Park Cancer Institute; 16Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 17Massachusetts General Hospital Cancer Center 18The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 19Fox Chase Cancer Center; 20Duke Cancer Institute; 21University of Michigan Comprehensive Cancer Center; 22UCSF Helen Diller Family Comprehensive Cancer Center; 23St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 24Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; and 25National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0018DOI Listing
February 2014

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.

Int J Cancer 2014 May 2;134(10):2284-93. Epub 2014 Jan 2.

Division of Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28561DOI Listing
May 2014

Abiraterone in metastatic prostate cancer.

N Engl J Med 2013 04;368(15):1458-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1301594DOI Listing
April 2013

Abiraterone acetate for the treatment of prostate cancer.

Expert Opin Pharmacother 2013 Jan 30;14(1):91-6. Epub 2012 Nov 30.

Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2013.745852DOI Listing
January 2013